Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Similar articles for PubMed (Select 23790737)

1.

Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.

Fujimoto N, Gemba K, Asano M, Fuchimoto Y, Wada S, Ono K, Ozaki S, Kishimoto T.

Respir Investig. 2013 Jun;51(2):92-7. doi: 10.1016/j.resinv.2013.02.002. Epub 2013 Mar 19.

PMID:
23790737
2.

Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.

Atagi S, Ogawara M, Kawahara M, Sakatani M, Furuse K, Ueda E, Yamamoto S.

Jpn J Clin Oncol. 1997 Oct;27(5):293-7.

3.

Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.

Fujii M, Fujimoto N, Hiraki A, Gemba K, Aoe K, Umemura S, Katayama H, Takigawa N, Kiura K, Tanimoto M, Kishimoto T.

Cancer Sci. 2012 Mar;103(3):510-4. doi: 10.1111/j.1349-7006.2011.02180.x. Epub 2012 Jan 13.

PMID:
22146010
4.

Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.

Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.

Lung Cancer. 2013 Dec;82(3):491-8. doi: 10.1016/j.lungcan.2013.09.016. Epub 2013 Oct 9.

PMID:
24161718
5.

Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.

Pettersson T, Fröseth B, Riska H, Klockars M.

Chest. 1988 Nov;94(5):1037-9.

PMID:
3180855
6.

Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.

Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A.

Clin Biochem. 2009 Jul;42(10-11):1046-50. doi: 10.1016/j.clinbiochem.2009.03.007. Epub 2009 Mar 18.

PMID:
19302997
7.

Serum concentration of integrin-linked kinase in malignant pleural mesothelioma and after asbestos exposure.

Watzka SB, Posch F, Pass HI, Flores RM, Hannigan GE, Bernhard D, Weber M, Mueller MR.

Eur J Cardiothorac Surg. 2013 May;43(5):940-5. doi: 10.1093/ejcts/ezs521. Epub 2012 Oct 7.

8.

Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.

Fuhrman C, Duche JC, Chouaid C, Abd Alsamad I, Atassi K, Monnet I, Tillement JP, Housset B.

Clin Biochem. 2000 Jul;33(5):405-10.

PMID:
11018693
9.

Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.

Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA.

Virchows Arch. 2007 Apr;450(4):455-61. Epub 2007 Feb 15.

PMID:
17377812
10.

Osteopontin is not a specific marker in malignant pleural mesothelioma.

Paleari L, Rotolo N, Imperatori A, Puzone R, Sessa F, Franzi F, Meacci E, Camplese P, Cesario A, Paganuzzi M.

Int J Biol Markers. 2009 Apr-Jun;24(2):112-7.

PMID:
19634115
11.

Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.

Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.

J Thorac Oncol. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b.

PMID:
23777840
12.

Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.

Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C.

N Engl J Med. 2012 Oct 11;367(15):1417-27. doi: 10.1056/NEJMoa1115050. Erratum in: N Engl J Med. 2012 Nov;367(18):1768.

13.

Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.

Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T.

Clin Chem Lab Med. 2011 Oct;49(10):1721-6. doi: 10.1515/CCLM.2011.242. Epub 2011 Jun 22.

PMID:
21692685
14.

Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.

Fujimoto N, Gemba K, Asano M, Wada S, Ono K, Ozaki S, Kishimoto T.

Exp Ther Med. 2010 Mar;1(2):313-317. Epub 2010 Mar 1.

15.

[A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].

Inoue C, Kato S, Higuchi K, Inoue H.

Nihon Kokyuki Gakkai Zasshi. 2007 Mar;45(3):243-7. Japanese.

PMID:
17419436
16.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
17.

The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.

Muraoka T, Soh J, Toyooka S, Aoe K, Fujimoto N, Hashida S, Maki Y, Tanaka N, Shien K, Furukawa M, Yamamoto H, Asano H, Tsukuda K, Kishimoto T, Otsuki T, Miyoshi S.

Lung Cancer. 2013 Dec;82(3):485-90. doi: 10.1016/j.lungcan.2013.09.017. Epub 2013 Oct 10.

PMID:
24168922
18.

Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma.

Hirayama N, Tabata C, Tabata R, Maeda R, Yasumitsu A, Yamada S, Kuribayashi K, Fukuoka K, Nakano T.

Respir Med. 2011 Jan;105(1):137-42. doi: 10.1016/j.rmed.2010.10.010. Epub 2010 Oct 30.

19.

Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.

Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2013 Jun;33(6):2707-13.

PMID:
23749930
20.

Hyaluronan in pleural effusions and in serum.

Hillerdal G, Lindqvist U, Engström-Laurent A.

Cancer. 1991 May 1;67(9):2410-4.

PMID:
2013045
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk